Pick your research goal.

Retatrutide (LY3437943) is a GLP-1 / GIP / glucagon triple agonist. It simultaneously targets three receptor pathways involved in energy intake, gastric emptying, and glucagon-driven lipolysis. Phase 2 trial data (Jastreboff et al., 2023) showed up to 24.2% body weight reduction at 48 weeks. the strongest weight-loss signal in the GLP-1 class to date.

Retatrutide has a long half-life (~6 days based on phase 2 pharmacokinetics), making it suitable for once-weekly research protocols. The slow titration ladder used in trials (low starting dose stepped up every 2-4 weeks) is what's reflected in the starter stack above.

In multi-compound metabolic research contexts, retatrutide is sometimes paired with MOTS-c (mitochondrial-derived peptide affecting AMPK and substrate utilization) or AOD-9604 (hGH fragment 176-191 for direct adipocyte lipolysis), investigating whether targeting multiple metabolic nodes simultaneously produces additive effects on substrate oxidation and fat mass.

BPC-157 is a stable gastric pentadecapeptide. It promotes angiogenesis via VEGF upregulation, accelerates tendon-to-bone healing in animal models, and modulates gut-brain axis signaling. It has been most extensively studied in gut barrier research and musculoskeletal repair models (Sikiric et al., 2018).

TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, differentiation, and new blood vessel formation. It has been studied in cardiac repair, wound healing, and neurological injury models. It complements BPC-157 by acting on different repair pathways. cytoskeletal dynamics vs. growth-factor signaling.

Why they're paired: BPC-157 and TB-500 are commonly combined in musculoskeletal and soft-tissue repair research (and pre-blended as "Wolverine Blend"). They operate on distinct but complementary pathways: BPC-157 focuses on vascularization and growth-factor signaling; TB-500 targets actin dynamics and cell migration. Adding GHK-Cu introduces an extracellular-matrix remodeling dimension, which is why the GLOW and KLOW blends layer it in.

GHK-Cu is a copper tripeptide that stimulates collagen, glycosaminoglycan, and decorin synthesis. It promotes wound healing and skin matrix remodeling. Research in the Pickart lab demonstrated regulation of over 4,000 human genes. including those controlling collagen turnover and anti-inflammatory pathways. It also increases collagen synthesis and density, reduces fine lines via matrix metalloproteinase (MMP) regulation, and acts as a potent antioxidant. It is well-studied in both in-vitro and human topical research.

Epithalon, a tetrapeptide from the pineal gland region, is a frequent skin/anti-aging research adjunct. focused on telomerase activation and telomere elongation in human cells (Khavinson et al., 2003). studied in cellular aging models as a potential longevity signal.

Why GLOW / KLOW exist: GLOW (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg per vial) and KLOW (the same plus KPV anti-inflammatory) are pre-formulated research blends targeting skin and repair pathways simultaneously. collagen matrix (GHK-Cu) plus vascular/repair signaling (BPC + TB-500) plus inflammatory modulation (KPV in KLOW).

NAD+ is a co-factor that declines with age and is required for sirtuin-mediated DNA repair and mitochondrial function. It is included in longevity-focused research contexts to assess metabolic interaction effects. Neuronal NAD+ supports SIRT1 / SIRT3 activity required for mitochondrial health, DNA repair, and axonal protection; NAD+ depletion has been linked to neurodegeneration in preclinical models, and restoration studies are an active research area.

MOTS-c is a mitochondrial-derived peptide. It improves insulin sensitivity and activates the AMPK pathway, enhancing metabolic substrate utilization. In animal models, MOTS-c prevented diet-induced obesity via mitochondrial biogenesis effects (Lee et al., 2015). It has a shorter half-life than most weekly research peptides, which is why typical protocols use daily or every-other-day administration.

Compound-specific research literature is also curated on the individual research pages for each peptide.

CJC-1295 (No DAC) is a GHRH analog. It binds GHRH receptors in the pituitary to stimulate GH synthesis and release. Without the DAC (Drug Affinity Complex), it has a shorter action window, allowing more physiological GH pulsatility in research protocols.

Ipamorelin is a selective GHRP. It stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating cortisol, prolactin, or ACTH. That selectivity profile (Raun et al., 1998) makes it the standard GHRP reference compound for mechanistic GH research.

Synergistic mechanism: CJC-1295 and ipamorelin act on two separate receptor pathways (GHRH-R and GHS-R1a) that converge on somatotrophs in the anterior pituitary. The combination produces greater GH release than either compound alone in preclinical models, reflecting the same principle as endogenous GHRH + ghrelin co-stimulation. This pair is the most studied GHRH / GHRP research combination in the literature.

Timing reference: GHRH + GHRP combinations are typically studied at fasting timepoints (>2 hr post-feeding) to minimize somatostatin blunting of GH release. Most research protocols use 2-3x daily administration windows.

Semax is an ACTH(4-7)PGP heptapeptide. It upregulates BDNF and NGF expression in preclinical models (Dolotov et al., 2006). It has been studied for neuroprotective properties after ischemic events in Russian clinical research. Not FDA-approved; for research only.

Selank is a tuftsin-derived hexapeptide with anxiolytic properties. It modulates GABA-A and serotonin receptor activity. It has been studied for cognitive enhancement and anxiety reduction in animal models without the sedative profile of benzodiazepines (Zozulya et al., 2001).

Complementary CNS targets: Semax and Selank are often paired in Russian-origin nootropic research because they target different aspects of cognitive function. Semax for neurotrophin upregulation and neuroprotection; Selank for GABAergic and serotonergic anxiety modulation. NAD+ is sometimes added in this context as a metabolic support compound, given neuronal dependence on NAD+ for energy production and epigenetic regulation.

Note: Semax and Selank are intranasal peptides in many of the original clinical research protocols, though all Purity Peptides compounds are supplied as lyophilized powder for research reconstitution only.